CN1969955A - Health-preserving capsule of edible fungus, preparation method and use thereof - Google Patents
Health-preserving capsule of edible fungus, preparation method and use thereof Download PDFInfo
- Publication number
- CN1969955A CN1969955A CNA200610098139XA CN200610098139A CN1969955A CN 1969955 A CN1969955 A CN 1969955A CN A200610098139X A CNA200610098139X A CN A200610098139XA CN 200610098139 A CN200610098139 A CN 200610098139A CN 1969955 A CN1969955 A CN 1969955A
- Authority
- CN
- China
- Prior art keywords
- group
- edible fungus
- health
- mice
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses health capsules containing edible mushrooms and process for preparation, wherein the raw materials include ganoderma lucidum, Hirsutella hepiali Chen et Shen, hedgehog hydnum and schisandra fruit. The capsules have good effect in improving human immunity and protecting liver from chemical damages.
Description
Technical field:
The present invention relates to a kind of health product.
Background technology:
Existing health product kind is numerous, but can play the product that improves immunity real belong to few, and poor effect often.
Summary of the invention:
The object of the present invention is to provide a kind of health-preserving capsule of edible fungus and production method that can effectively improve the immunity effect.
Technical solution of the present invention is:
A kind of health-preserving capsule of edible fungus is characterized in that: the raw material by following weight item is made:
Ganoderma 30~50%
Hirsutella hepiali Chen et Shen powder 10~30%
Hericium erinaceus (Bull. Ex Fr.) Pers. 10~30%
Fructus Schisandrae Chinensis 5~15%, above-mentioned raw materials weight sum is 100%.
Described health-preserving capsule of edible fungus, make by the raw material of following weight item:
Ganoderma 40%
Hirsutella hepiali Chen et Shen powder 20%
Hericium erinaceus (Bull. Ex Fr.) Pers. 20%
Fructus Schisandrae Chinensis 10%.
A kind of production method of health-preserving capsule of edible fungus is characterized in that: comprise the following steps:
(1) with Ganoderma 30~50wt%, Hericium erinaceus (Bull. Ex Fr.) Pers. 10~30wt%, Fructus Schisandrae Chinensis 5~15wt% cleaning, 10 mesh sieves are crossed in dry, pulverizing back, and it is standby to get coarse grain;
(2) above-mentioned Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., Fructus Schisandrae Chinensis being decocted with water, be concentrated into proportion is 1.40 extractum;
(3) the extractum drying under reduced pressure that step (2) is obtained becomes dry extract, pulverizes 80~100 mesh sieves, gets dry extract;
(4) dry extract and Hirsutella hepiali Chen et Shen powder 10~30wt% are stirred, get mixed powder; Add 85% ethanol again, addition is controlled at 10~30% of mixed powder weight, makes soft material; Through granulation, sterilization, dry, filled capsules, get product again.
The application of health-preserving capsule of edible fungus in preparation enhancing immunity goods.
The application of health-preserving capsule of edible fungus in preparation acute chemical hepatic injury goods.
Product of the present invention has good raising immunity effect, chemical liver injury is had auxiliary protection function, and raw material is easy to get.
The invention will be further described below in conjunction with embodiment.
The specific embodiment:
A kind of production method of health-preserving capsule of edible fungus is characterized in that: comprise the following steps:
(1) Ganoderma 30~50wt% (example 30%, 40%, 50%), Hericium erinaceus (Bull. Ex Fr.) Pers. 10~30wt% (example 10%, 20%, 30%), Fructus Schisandrae Chinensis 5~15wt% (example 5%, 10%, 15%) are cleaned, 10 mesh sieves are crossed in 80 ℃ of dryings, pulverizing backs, and it is standby to get coarse grain;
(2) above-mentioned Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., Fructus Schisandrae Chinensis are decocted with water 2 times, for the first time add 10 times of decoctings to boil, add 8 times of water gagings the 2nd time to decoct, each 2 hours, precipitation was filtered, and merging filtrate is concentrated into proportion and is 1.40 extractum;
(3) extractum that step (2) is obtained drying under reduced pressure under 0.08Mpa, 80 ℃ of conditions becomes dry extract, pulverizes 80~100 mesh sieves (example 80,90,100 orders), dry extract;
(4) with dry extract and Hirsutella hepiali Chen et Shen powder 10~30wt% (example 10%, 20%, 30%) with trough type mixing machine fully stir, mixing, mixed powder; Add food stage 85% ethanol again, addition is controlled at 10~30% (examples 10%, 20%, 30%) of mixed powder weight, makes soft material; After 16 order stainless steel sifts, granulation, sterilization (105 ℃, 30 minutes), dry (70 ℃, 240 minutes), filled capsules gets product.Above-mentioned raw materials Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., Fructus Schisandrae Chinensis, Hirsutella hepiali Chen et Shen grain weight amount sum are 100%.Product is applied in the preparation enhancing immunity goods and prepares in the acute chemical hepatic injury goods.
(1) product of the present invention (claim again: hundred bacterium are good for edible fungus capsule) is to CCL
4The protective effect of the chmice acute chemical liver injury that causes
1 material and method
1.1 sample: hundred bacterium are good for edible capsule, and content is a chocolate brown powder, is provided by Jiangsu Anhui Biology Science Co., Ltd.Sample is the 0.5g/ grain, seals, puts shady and cool dry place, and storage life is 24 months, and the human body recommended intake is 4.5g/ people/d, in this test by 75mg/kg b.wt./d.
1.2 laboratory animal: select for use the healthy male ICR mouse of Shanghai west 18~22g that pul-Bi Kai laboratory animal company limited provides (2 grades, animal card number: SCXK (Shanghai) 2003-0002 number) 50, be divided into 5 groups at random by body weight, 10 every group.Environment card number: SYXK (Soviet Union) 2002-0004; Animal feed source and card number: Jiangpu development laboratory animal feed factory, No. 95001, moving (raising) word of Soviet Union.
1.3 dosage design: it is 4.5g that the adult recommends newspaper to go into amount (by the 60kg weighing machine) every day, 375,750, three sample dose groups of 2250mg/kg b.wt../d (be equivalent to respectively be grown up per kg body weight per day recommended intake 5 times, 10 times and 30 times) and negative control group, model control group (distilled water) be 75mg/kgb.wt/d, experiment is established:.Give mice per os every day and irritate stomach, the blood sampling separation of serum is surveyed ALT, AST behind the continuous irrigation stomach 30d, gets liver and does histopathologic examination, and the mouse stomach volume is that 20ml/kg b.wt. matched group is irritated distilled water.
1.4 key instrument and reagent: electronic balance, automatic clinical chemistry analyzer.Main agents: carbon tetrachloride (CCL
4, AR, Shanghai Changjiang River chemical plant), ALT and AST measure test kit (Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.).
1.5 test method: take by weighing sample 1875,3750,11250mg, add distilled water respectively and be mixed with each group to 100ml and be subjected to test solution (per two days preparation once), per os is irritated stomach and is given mice, matched group and CCL
4Model group gives distilled water, irritates the stomach volume and is 20ml/kg b.wt.., to the 30th day, with each treated animal fasting 16h overnight, each sample dose group and CCL
4Model group is irritated to prepare 0.8% (v/v) CCL with salad oil with the amount of 5ml/kg.b.wt.
4Solution is set up the acute liver damage model, and negative control group is irritated salad oil with the amount of 5ml/kg.b.wt..Each treated animal is all in CCL
4Liver is got in 24h blood sampling behind the/salad oil filling stomach, measures ALT, AST activity behind the separation of serum, and hepatic tissue is made routine pathology and learned inspection, observes the degree of hepatocellular degeneration, necrosis.
1.6 the experimental data statistics: this experiment gained mice weight data is a measurement data, initial data adopts the SPSS statistical software to carry out test of normality and homogeneity test of variance, satisfies the requirement of " variance is neat ".Reuse SPSS statistical software one factor analysis of variance method is added up.Active satisfied " variance the is neat " requirement after to number conversion of Serum ALT and AST uses one factor analysis of variance method (ANOVA) to add up then, and the data of P<0.05 are carried out statistical disposition with the comparative approach in twos of mean between a plurality of experimental grouies and matched group.Hepatic tissue degeneration, downright bad result carry out statistical procedures with rank test respectively.
2. experimental result
2.1 sample is to the influence of the weight of animals before and after the experiment
By table 1 as seen, respectively tried agent amount group mice body weight before and after the experiment and compared there was no significant difference (P>0.05) with matched group.
Respectively organize before and after table 1 experiment mice body weight (
)
Group | Number of animals (only) | Initial body weight (g) | Whole opisthosoma heavy (g) |
Negative control group CCl 4Model group sample 375mg/kg+CCl 4Group sample 750mg/kg+CCl 4Group sample 2250mg/kg+CCl 4Group | 10 10 10 10 10 | 20.4±1.3 20.7±1.2 20.5±1.3 20.7±1.1 20.7±1.2 | 29.8±2.8 30.1±2.1 29.9±2.8 30.3±2.4 28.5±1.8 |
2.2 sample is to acute CCL
4Hepatic injury mice serum ALT, AST activity influence
By table 2 as seen, negative control group and CCL
4Model group is compared Serum ALT, the AST activity all has utmost point significant difference, shows the modeling success; Middle and high dosage group ALT activity, middle dosage group AST activity and CCL
4The analog value of matched group compares, and difference has significance (P<0.05, P<0.01).
The strong edible fungus capsule of table 2 hundred bacterium is to acute CCL
4Hepatic injury mice serum ALT, AST activity (
) influence
Group | Number of animals (only) | ALT | AST | ||
IU/L | The P value | IU/L | The P value | ||
Negative control group CCl 4Model group sample 375mg/kg+CCl 4Group sample 750mg/kg+CCl 4Group sample 2250mg/kg+CCl 4Group | 10 10 10 10 10 | 47±12 634±117 584±111 509±103 510±45 | 0.000 - 0.349 0.015 0.025 | 177±35 705±107 707±119 429±177 579±90 | 0.000 - 0.999 0.000 0.060 |
2.3 sample is to acute CCL
4The influence of hepatic injury Mouse Liver pathological change
By table 3, table 4 as seen, each organizes pathological change based on hepatic cell fattydegeneration and coagulation necrosis, carries out statistical procedures with rank test respectively.The hepatic cell fattydegeneration of negative control group is compared with the carbon tetrachloride model group with coagulation necrosis, and there were significant differences, performance modeling success.Each dosage group steatosis all alleviates but not statistically significant than model.The coagulation necrosis of middle and high dosage group hepatic tissue is compared obviously with the carbon tetrachloride model group and is alleviated (P<0.05)
The strong edible fungus capsule of table 3 hundred bacterium is to acute CCL
4The influence of hepatic injury Mouse Liver pathological change scoring (unit: only)
Group | Negative control | The CCl4 model | The sample high dose | Dosage in the sample | The sample low dosage | |||||||||||||||||||||
Classification | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | |
Degeneration | Hydropic degeneration balloon sample becomes the steatosis acidophile degeneration | 10 10 10 10 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 10 10 4 9 | 0 0 5 1 | 0 0 1 0 | 0 0 0 0 | 0 0 0 0 | 10 10 8 10 | 0 0 2 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 10 10 6 10 | 0 0 3 0 | 0 0 1 0 | 0 0 0 0 | 0 0 0 0 | 10 10 8 10 | 0 0 2 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
Coagulation necrosis | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 6 | 4 | 0 | 0 | 0 | 7 | 3 | 0 | 0 | 0 | 4 | 5 | 1 |
Annotate: every group of 10 animals, in the classification, 0 for roughly normal, 1 expression degeneration or downright bad hepatocyte account for 1/4 of whole visual field, 2 expression degeneration or downright bad hepatocyte account for 2/4 of whole visual field, 3/4,4 expression degeneration or downright bad hepatocyte that 3 expression degeneration or downright bad hepatocyte account for whole visual field account for whole visual field.
The acute CCL of table 4
4The degeneration of hepatic injury mouse cell, the downright bad accumulative total submeter that changes
Group | Number of animals (only) | Steatosis | The acidophilia becomes | Coagulation necrosis | ||||||
Scoring | Average rank | The p value | Scoring | Average rank | The p value | Scoring | Average rank | The p value | ||
Negative control group CCL 4Model group sample 375mg/kg+CCL 4Group sample 750mg/kg+CCL 4Group sample 2250mg/kg+CCL 4Group | 10 10 10 l0 10 | 0 7 2 5 2 | 18.5 33.6 23.3 28.8 23.3 | 0.023 0.066 0.450 0.066 | 0 1 0 0 0 | 25.0 27.5 25.0 25.0 25.0 | 0.317 0.317 0.317 0.317 | 0 31 27 23 24 | 5.50 38.35 31.70 25.05 26.90 | 0.000 0.154 0.006 0.014 |
3. brief summary: per os gives hundred bacterium edible fungus capsule 30d of mice various dose, is respectively tried the used dosage group of thing mice body weight before and after the experiment and compares there was no significant difference (P>0.05) with matched group.After the acute liver damage modeling, middle and high dosage group serum alanine aminotransferase (ALT) and aspartic acid based transferase (AST) activity all are lower than CCL
4The model class value, middle and high dosage group ALT activity and CCL
4The analog value of matched group compares, and difference has significance (P<0.05), middle dosage group AST activity and CCL
4The analog value of matched group compares, and difference has extremely significantly meaning (P<0.01).Each dosage group hepatic pathology damage is all than CCL
4Matched group alleviates, and middle and high dosage group hepatic tissue coagulation necrosis change is compared obviously with the carbon tetrachloride model group and alleviated (P<0.0, P<0.05).To sum up, the strong edible fungus capsule of hundred bacterium has protective effect to the chmice acute chemical liver injury that carbon tetrachloride causes.
The strong edible fungus capsule enhancing immunity function zoopery report of hundred bacterium
1 material and method
1.1 sample: hundred bacterium are good for edible fungus capsule, and content is a brown ceramic powder, is provided by Jiangsu Anhui Biology Science Co., Ltd.Sample is the 0.5g/ grain, and preservation condition is sealing, puts shady and cool dry place, storage life 24 months, the human body recommended intake is the 4.5g/ day for human beings, in this test by 75mg/kg b.wt./d.
1.2 laboratory animal: select 18~22g Healthy female secondary ICR mice that Shanghai Slac Experimental Animal Co., Ltd. provides (animal card number: SCXK (Shanghai) 2004-0005 number) for use, respectively be divided into 4 groups at random by body weight respectively, every group 10, be divided into 5 batches and carry out mouse spleen lymphocyte conversion test and NK cytoactive mensuration respectively; The tardy paraphilia reaction of dinitrofluorobenzene inducing mouse (DTH) test; Antibody-producting cell detects and serum hemolysin is measured; The clearance test of mice carbon; Turnover of Mouse Peritoneal Macrophages is engulfed the chicken red blood cell test.Environment card number: SYXK (Soviet Union) 2002-0004; Animal feed source and card number: Jiangpu development laboratory animal feed factory, No. 95001, moving (raising) word of Soviet Union.
1.3 dosage design: adult's (by the 60kg weighing machine) recommended intake every day is 4500mg, be equivalent to 75mg/kg b.wt./d, 10 times of human body recommended amounts are established in experiment, be every day 750mg/kg b.wt. as in the dosage group, upper and lower each 1 dosage group: 2250mg/kg b.wt./d and 375mg/kg b.wt./d are as high dose group and low dose group (be equivalent to respectively human body recommended amounts 30 times and 5 times).Take by weighing sample 22500,7500,3750mg, add respectively distilled water to 200ml be mixed with each the group be subjected to test solution (to deposit in 4 ℃ of refrigerators, preparation in per two days once), per os is irritated stomach and is given mice, irritating the stomach volume is 20ml/kg b.wt., negative control group is irritated distilled water, surveys every immune indexes behind the continuous irrigation stomach 30d.
1.4 key instrument and reagent: electronic scale, electronic balance, microscope, microplate reader, CO2 gas incubator, card punch, 723 spectrophotometers, superclean bench, agitator, constant water bath box, timer, chroma tank, adjustable pipette, test tube, trace blood pipe, 200 eye mesh screens, 24 well culture plates, 96 well culture plates, operating theater instruments etc.
RPMI1640 cell culture fluid, YAC-1 cell, calf serum, 2 mercapto ethanol (2-ME), penicillin, streptomycin, concanavalin A, Con A (ConA), hydrochloric acid, isopropyl alcohol, MTT, Hank ' s liquid, PBS buffer (pH7.2-7.4), 2,4-dinitrofluorobenzene (DNCB), acetone, Oleum Sesami, sheep red blood cell (SRBC) (SRBC), complement (guinea pig serum), SA buffer, Dou Shi reagent, india ink, Na
2CO
3, EINECS 212-761-8, nitro tetrazolium chloride (INT), azophenlyene dimethyl ester sulfate (PMS), NAD, 0.2mol/L Tris-HCl buffer (pH8.2), 2.5%Triton etc.
1.5 experimental technique:
1.5.1 the tardy paraphilia reaction of dinitrofluorobenzene inducing mouse (DTH)
Behind the continuous irrigation stomach 25d, the mouse web portion unhairing, 1% dinitrofluorobenzene (DNFB) acetone Oleum Sesami solution 50ul smears sensitization.5d after the sensitization, mouse right ear evenly smear 1%DNFB acetone Oleum Sesami solution 10ul and attack, and left ear is smeared acetone Oleum Sesami solution and compared, attack back 24h and put to death mice, cut left and right sides auricular concha, weigh in the auricle of same position cut-off footpath 8mm, the difference of left and right sides auricle weight is as the swelling degree.Get thymus and the spleen of mice simultaneously, with the spleen of every 10g mice heavy (mg) and thymus weight (mg) as spleen/body weight ratio and thymus/body weight ratio.
1.5.2ConA inductive mouse spleen lymphocyte transformation experiment (mtt assay)
Behind the continuous continuous irrigation stomach 30d, the aseptic spleen of getting, (cell concentration is 3 * 10 to make the individual cells suspension
6Individual ml).Divide two holes to add in 24 well culture plates cell suspension, every hole 1ml, a hole adds 75ulConA liquid, and 5%CO is put in contrast in another hole
2, 37 ℃ of CO
2Cultivate 72h in the incubator.Cultivate and finish preceding 4h adding MTT (5mg/mL) 50ul/ hole, continue to cultivate.After cultivating end, every hole adds 1mL acid isopropyl alcohol, and the piping and druming mixing dissolves purple crystal fully.Divide then to install in 96 well culture plates, enzyme-linked immunosorbent assay instrument as parallel sample, is used in each hole packing 3 hole (200ul/ hole), measures optical density value with the 570nm wavelength.Deduct the optical density value that does not add the ConA hole with the optical density value that adds the ConA hole and represent lymphocytic multiplication capacity.
1.5.3 antibody-producting cell detects (PFC)
Behind the continuous irrigation stomach 25d, every Mus lumbar injection 2% (v/v) hematocrit SRBC 0.2ml sensitization.Behind the immunity 5d, the dislocation of mice cervical vertebra is put to death, take out spleen, make single cell suspension, carry out hemolytic plaque test.Counting hemolysis plaque number is with plaque number/10
6Splenocyte is represented the antibody-producting cell number.
1.5.4 serum hemolysin is measured: half hemolysis value (HC
50) algoscopy
Behind the continuous irrigation stomach 25d, every Mus lumbar injection 2% (v/v) hematocrit SRBC 0.2ml sensitization.Behind the immunity 5d, mice is plucked eyeball blood sampling, gets serum and surveys hemolytic reaction, and other establishes not that the control tube of increase serum (replacing with the SA buffer) is the colorimetric blank, measures respectively in 540nm and respectively manages optical density value.Be calculated as follows the sample HC of each Mus
50:
1.5.5 mice carbon clearance test
The india ink 0.1ml of the every 10g body weight of mice tail vein injection 1: 3 (v/v) dilution behind the continuous irrigation stomach 30d, timing immediately after the injection, and respectively at 2,10min gets blood 20 μ l from the angular vein clump, is added in 2ml 0.1% sodium carbonate, surveys OD
600nmAnd get liver, spleen is weighed, by formula
Ask mice phagocytic index a value (K=(lgOD
1-lgOD
2)/(t
2-t
1)).
1.5.6 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (dripping the sheet method)
Behind the continuous irrigation stomach 26d, every Mus lumbar injection 2% (v/v) hematocrit SRBC 0.2ml activates mouse macrophage.Behind the 4d, the cervical vertebra dislocation method is put to death mice, and lumbar injection adds Hank ' s liquid 4mL/ of calf serum, draws 1% chicken red blood cell mixing of abdominal cavity washing liquid and equivalent.Draw the 0.5mL mixed liquor, add in the agar circle of slide, place incubator and hatched 20 minutes for interior 37 ℃.Hatch finish the back with normal saline not attached cell wash out, in methanol solution, fix 1 minute, Giemsa liquid dyeing 15 minutes.(phagocytic rate is in per 100 macrophages, engulfs the shared percentage rate of macrophage of chicken red blood cell with 40 * microscopic counting phagocytic rate and phagocytic index; Phagocytic index is the number of average each macrophage phagocytic chicken red blood cell).And judge the phagocytic activity of macrophage in view of the above.
1.5.7NK cytoactive is measured
Behind the continuous irrigation stomach 30d, the aseptic spleen of getting, (cell concentration is 2 * 10 to make the individual cells suspension
7Individual/mL), the action effect cell.Get target cell (YAC-1 cell) and each 100ul of effector lymphocyte (imitating target), add in U type 96 well culture plates than 50: 1; Target cell nature release aperture adds target cell and each 100ul of culture fluid, and the maximum release aperture of target cell adds target cell and each 100ul of 2.5%Triton; Above-mentioned every three repeating holes of all establishing are in 37 ℃, 5%CO
2Cultivate 4h in the incubator, then with 96 well culture plates with the centrifugal 5min of 1500r/min, draw at the bottom of the supernatant 100ul horizontalization in 96 well culture plates in every hole, add LDH substrate liquid 100ul simultaneously, reaction 3min, every hole adds the HCl 30ul of 1mol/L, measures optical density value (OD) at microplate reader 490nm place.
Be calculated as follows the NK cytoactive:
1.6 experimental data statistics:
This experiment gained mice body weight, dirty body ratio, optical density value, swelling degree, hemolysis plaque number, HC
50, data such as phagocytic rate and phagocytic index, mice phagocytic index a, NK cytoactive are measurement data, initial data (wherein phagocytic rate is behind square arcsine transformation) adopts the SPSS statistical software to carry out test of normality and homogeneity test of variance, satisfy " variance is neat " and " normal distribution " requirement, reuse SPSS statistical software one factor analysis of variance method is added up, and the data of P<0.05 are carried out statistical disposition with the comparative approach in twos of mean between a plurality of experimental grouies and matched group.
2 experimental results
2.1 sample is to the influence of the weight of animals before and after the experiment
By table 1, table 2, as seen table 3 is respectively tried the weightening finish of agent amount group mice and is compared there was no significant difference (P>0.05) with matched group before and after the experiment.
Group | Drench the active group of commentaries on classics/NK | Tardy paraphilia reaction group | PFC/HC 50Group | |||
Body weight (g) | The P value | Body weight (g) | The P value | Body weight (g) | The P value | |
Dosage group high dose group in the matched group low dose group | 20.7±0.8 20.6±0.9 20.4±0.9 20.5±0.7 | --- >0.05 >0.05 >0.05 | 20.6±1.0 20.4±0.8 20.5±0.8 20.5±0.7 | --- >0.05 >0.05 >0.05 | 20.3±0.7 20.3±0.8 20.4±0.8 20.1±0.8 | --- >0.05 >0.05 >0.05 |
Table 1 (continuing) respectively organize mice initial body weight (
)
Group | Peritoneal macrophage is engulfed group | Carbon is cleaned up group | ||
Body weight (g) | The P value | Body weight (g | The P value | |
Dosage group high dose group in the matched group low dose group | 20.0±0.8 20.2±0.9 20.1±1.0 19.8±0.9 | --- >0.05 >0.05 >0.05 | 19.2±0.6 19.1±0.5 19.1±0.6 19.1±0.7 | --- >0.05 >0.05 >0.05 |
Group | Drench the active group of commentaries on classics/NK | Tardy paraphilia reaction group | PFC/HC 50Group | |||
Body weight (g) | The P value | Body weight (g) | The P value | Body weight (g) | The P value | |
Dosage group high dose group in the matched group low dose group | 34.4±2.6 34.6±2.2 34.0±0.8 34.4±2.5 | --- >0.05 >0.05 >0.05 | 34.7±3.0 32.3±2.5 34.3±2.4 34.9±2.0 | --- >0.05 >0.05 >0.05 | 34.4±3.0 33.6±1.7 34.3±2.7 34.0±1.7 | --- >0.05 >0.05 >0.05 |
Table 2 (continuing) test end respectively organize mice body weight (
)
Group | Peritoneal macrophage is engulfed group | Carbon is cleaned up group | ||
Body weight (g) | The P value | Body weight (g) | The P value | |
Dosage group high dose group in the matched group low dose group | 33.1±1.9 33.0±2.2 33.4±1.5 32.0±1.4 | --- >0.05 >0.05 >0.05 | 31.8±1.5 31.7±2.0 32.2±2.9 33.1±1.3 | --- >0.05 >0.05 >0.05 |
Group | Drench the active group of commentaries on classics/NK | Tardy paraphilia reaction group | PFC/HC 50Group | |||
Weight increase (g) | The P value | Weight increase (g) | The P value | Weight increase (g) | The P value | |
Dosage group high dose group in the matched group low dose group | 13.7±2.8 14.0±2.8 13.6±1.1 13.9±2.3 | --- >0.05 >0.05 >0.05 | 14.1±3.0 11.9±2.7 13.8±2.3 14.5±1.8 | --- >0.05 >0.05 >0.05 | 14.0±3.2 13.3±1.8 13.9±3.0 13.9±1.5 | --- >0.05 >0.05 >0.05 |
Table 3 (continuing) sample to the influence of mice weight increase (
)
Group | Peritoneal macrophage is engulfed group | Carbon is cleaned up group | ||
Weight increase (g) | The P value | Weight increase (g) | The P value | |
Dosage group high dose group in the matched group low dose group | 13.1±2.2 12.9±2.5 13.4±1.9 12.2±2.0 | --- >0.05 >0.05 >0.05 | 12.6±1.6 12.6±2.0 13.1±3.1 14.0±1.4 | --- >0.05 >0.05 >0.05 |
Sample is to the influence of internal organs/body weight ratio
By table 4 as seen, each organizes mouse thymus/body ratio, spleen body ratio is compared there was no significant difference (P>0.05) with matched group
The strong edible fungus capsule of table 4 hundred bacterium is to the influence of mice internal organs (mg)/body weight (10g) ratio
2.3 cellular immune function test: the tardy paraphilia reaction of the inductive mice of dinitrofluorobenzene (DNFB) (DTH)
By table 5 as seen, the auricle swelling degree of each dosage group mice all is higher than the solvent control class value, but the result reaches comparative statistics processing in twos through variance analysis, and each dosage group does not all have statistical significant difference (P>0.05).Point out the strong edible fungus capsule of hundred bacterium not have and to strengthen the tardy paraphilia reagentia of mice that DNFB causes.
The strong edible fungus capsule of table 5 hundred bacterium is to the influence of the tardy paraphilia reaction of Mice Auricle
2.4 cellular immune function test: the inductive mouse spleen lymphocyte transformation experiment of ConA (mtt assay)
By table 6 as seen, each dosage group optical density difference all is higher than the solvent control class value, and increases with dosage, and through variance analysis and comparative statistics processing in twos, middle and high dosage group all has statistical significant difference (P<0.01).Point out the strong edible fungus capsule of middle and high dosage hundred bacterium can strengthen the mouse lymphocyte multiplication capacity.
The influence that the strong edible fungus capsule of table 6 hundred bacterium transforms mouse spleen lymphocyte
Group | Take in dosage (mg/kg/d) every day | Number of animals (only) | Optical density value | Optical density difference | The P value | |
-ConA | +ConA | |||||
Control sample | 0 375 750 2250 | 10 10 10 10 | 0.103±0.005 0.097±0.009 0.105±0.009 0.128±0.014 | 0.252±0.042 0.256±0.037 0.335±0.064 0.404±0.059 | 0.149±0.039 0.159±0.035 0.230±0.059 0.276±0.052 | --- 0.566 0.002 0.000 |
2.5 the humoral immune function test: antibody-producting cell detects (Jerne improves slide method)
By table 7 as seen, each dosage group plaque number average is higher than the solvent control class value, and increases with dosage, and through variance analysis and comparative statistics processing in twos, middle and high dosage group plaque number has been compared significant difference (P<0.01) with the contrast class value.Point out the strong edible fungus capsule of middle and high dosage hundred bacterium to have the ability that mice produces antibody-producting cell that strengthens.
The strong edible fungus capsule of table 7 hundred bacterium is to the influence of mice spleen antibody-producting cell amount
2.6 humoral immune function test: serum hemolysin test
By table 8 as seen, each dosage group mice serum half hemolysis value (HC
50) compare with the contrast class value, through variance analysis and comparative statistics processing in twos, middle and high dosage group all has statistical significant difference (P<0.01).Point out the strong edible fungus capsule of middle and high dosage hundred bacterium can strengthen the ability that mice produces serum hemolysin.
The strong edible fungus capsule of table 8 hundred bacterium is to the influence of serum hemolysin level
2.7 monokaryon-macrophage function test: mice carbon clearance test
By table 9 as seen, the phagocytic index a of each dosage group mice compares with the solvent control class value, through variance analysis and comparative statistics processing in twos, all no difference of science of statistics (P>0.05).Point out the strong edible fungus capsule of hundred bacterium not have and strengthen the effect that mice carbon is cleaned up ability.
The influence that the strong edible fungus capsule of table 9 hundred bacterium is cleaned up mice carbon (
)
Group | Take in dosage (mg/kg/d) every day | Number of animals (only) | The K value | Phagocytic index a | The P value |
Control sample | 0 375 750 2250 | 10 10 10 10 | 0.0441±0.012 0.0518±0.008 0.0449±0.012 0.0429±0.009 | 6.771±1.48 6.740±0.59 6.912±0.71 6.851±0.53 | --- 0.951 0.788 0.873 |
2.8 monokaryon-macrophage function test: Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell
Phagocytic rate and phagocytic index by visible each the dosage group mice of table 10 all are higher than the solvent control group, and raise with the dosage increase, through variance analysis and comparative statistics processing in twos, middle and high dosage group phagocytic rate and high dose group phagocytic index have significant difference (P<0.05, P<0.01) respectively.Prompting, the strong edible fungus capsule of middle and high dosage hundred bacterium has the effect that strengthens the Turnover of Mouse Peritoneal Macrophages phagocytic activity.
The strong edible fungus capsule of table 10 hundred bacterium to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic activity (
)
Group | Take in dosage (mg/kg/d) every day | Number of animals (only) | Phagocytic rate (%) | The P value | Phagocytic index | The P value |
Control sample | 0 375 750 2250 | 10 10 10 10 | 9.8±2.9 12.9±6.1 13.1±2.9 14.9±4.6 | 0.871 0.027 0.007 | 0.138±0.055 0.166±0.085 0.167±0.053 0.216±0.072 | 0.394 0.243 0.014 |
2.9NK cytoactive is measured
NK cytoactive by visible each the dosage group mice of table 11 all is higher than the solvent control group, and increase with dosage, the result is through variance analysis and comparative statistics processing in twos, middle and high dosage group all has statistical significant difference (P<0.01), shows that the strong edible fungus capsule of middle and high dosage hundred bacterium all has the active effect of the NK cells in mice of enhancing.
The strong edible fungus capsule of table 11 hundred bacterium to the active influence of NK cells in mice (
)
Group | Take in dosage (mg/kg/d) every day | Number of animals (only) | NK cytoactive (%) | The P value |
Control sample | 0 375 750 2250 | 10 10 10 10 | 83.1±12.2 92.7±10.2 108.1±20.6 116.4±25.4 | --- 0.071 0.004 0.001 |
3 brief summaries: per os gives the strong edible fungus capsule 30d of hundred bacterium of mice various dose, and weight of mice is not had influence; The strong edible fungus capsule of middle and high dosage hundred bacterium all has the mouse lymphocyte of increasing multiplication capacity, strengthen the ability that mice produces serum hemolysin and mice generation antibody-producting cell, strengthen the Turnover of Mouse Peritoneal Macrophages phagocytic activity and strengthen the active effect of NK cells in mice.According to health food enhancing immunity functional evaluation standard, the strong edible fungus capsule of hundred bacterium has the function of enhancing immunity.
Claims (5)
1, a kind of health-preserving capsule of edible fungus is characterized in that: the raw material by following weight item is made:
Ganoderma 30~50%
Hirsutella hepiali Chen et Shen powder 10~30%
Hericium erinaceus (Bull. Ex Fr.) Pers. 10~30%
Fructus Schisandrae Chinensis 5~15%, above-mentioned raw materials weight sum is 100%.
2, health-preserving capsule of edible fungus according to claim 1 is characterized in that: the raw material by following weight item is made:
Ganoderma 40%
Hirsutella hepiali Chen et Shen powder 20%
Hericium erinaceus (Bull. Ex Fr.) Pers. 20%
Fructus Schisandrae Chinensis 10%.
3, a kind of production method of health-preserving capsule of edible fungus is characterized in that: comprise the following steps:
(1) with Ganoderma 30~50wt%, Hericium erinaceus (Bull. Ex Fr.) Pers. 10~30wt%, Fructus Schisandrae Chinensis 5~15wt% cleaning, 10 mesh sieves are crossed in dry, pulverizing back, and it is standby to get coarse grain;
(2) above-mentioned Ganoderma, Hericium erinaceus (Bull. Ex Fr.) Pers., Fructus Schisandrae Chinensis being decocted with water, be concentrated into proportion is 1.40 extractum;
(3) the extractum drying under reduced pressure that step (2) is obtained becomes dry extract, pulverizes 80~100 mesh sieves, gets dry extract;
(4) dry extract and Hirsutella hepiali Chen et Shen powder 10~30wt% are stirred, get mixed powder; Add 85% ethanol again, addition is controlled at 10~30% of mixed powder weight, makes soft material; Through granulation, sterilization, dry, filled capsules, get product again.
4, the application of the described health-preserving capsule of edible fungus of a kind of claim 1 in preparation enhancing immunity goods.
5, the application of the described health-preserving capsule of edible fungus of a kind of claim 1 in preparation acute chemical hepatic injury goods.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200610098139XA CN1969955A (en) | 2006-11-29 | 2006-11-29 | Health-preserving capsule of edible fungus, preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200610098139XA CN1969955A (en) | 2006-11-29 | 2006-11-29 | Health-preserving capsule of edible fungus, preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1969955A true CN1969955A (en) | 2007-05-30 |
Family
ID=38111103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200610098139XA Pending CN1969955A (en) | 2006-11-29 | 2006-11-29 | Health-preserving capsule of edible fungus, preparation method and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1969955A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013155713A1 (en) * | 2012-04-20 | 2013-10-24 | 江苏安惠生物科技有限公司 | Ganoderma lucidum composite capsule |
CN104560549A (en) * | 2014-11-29 | 2015-04-29 | 陈程 | Pine mushroom health-care liquor and preparation method thereof |
CN107441126A (en) * | 2017-08-01 | 2017-12-08 | 李庆杰 | It is a kind of that there is macro fungi composition for improving NK cell tumour killing activities and preparation method thereof |
CN109222061A (en) * | 2018-09-25 | 2019-01-18 | 临沂信邦生物科技有限公司 | Hirsutella hepiali Chen et Shen edible mushroom piece and preparation method |
WO2019024017A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Chinese medicine capsule for use in enhancing immunity |
CN112772907A (en) * | 2021-03-05 | 2021-05-11 | 江西仙客来生物科技有限公司 | Lucid ganoderma and hericium erinaceus oral liquid and preparation method thereof |
-
2006
- 2006-11-29 CN CNA200610098139XA patent/CN1969955A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013155713A1 (en) * | 2012-04-20 | 2013-10-24 | 江苏安惠生物科技有限公司 | Ganoderma lucidum composite capsule |
CN104560549A (en) * | 2014-11-29 | 2015-04-29 | 陈程 | Pine mushroom health-care liquor and preparation method thereof |
CN107441126A (en) * | 2017-08-01 | 2017-12-08 | 李庆杰 | It is a kind of that there is macro fungi composition for improving NK cell tumour killing activities and preparation method thereof |
CN107441126B (en) * | 2017-08-01 | 2021-09-10 | 李庆杰 | Macro-fungus composition capable of improving NK cell tumor killing activity and preparation method thereof |
WO2019024017A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Chinese medicine capsule for use in enhancing immunity |
CN109222061A (en) * | 2018-09-25 | 2019-01-18 | 临沂信邦生物科技有限公司 | Hirsutella hepiali Chen et Shen edible mushroom piece and preparation method |
CN112772907A (en) * | 2021-03-05 | 2021-05-11 | 江西仙客来生物科技有限公司 | Lucid ganoderma and hericium erinaceus oral liquid and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rashedy et al. | Evaluation and characterization of alginate extracted from brown seaweed collected in the Red Sea | |
CN1969955A (en) | Health-preserving capsule of edible fungus, preparation method and use thereof | |
CN102671009B (en) | Fermented plant extract and powder thereof with and combinations thereof the manufacture method of thing | |
Nowacka-Jechalke et al. | Promising potential of crude polysaccharides from Sparassis crispa against colon cancer: An in vitro study | |
Li et al. | Extraction, characterization, antitumor and immunological activities of hemicellulose polysaccharide from Astragalus radix herb residue | |
CN104592411B (en) | Phosphoric acid esterification snakegourd peel polysaccharide and medical application thereof | |
CN103800390A (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
CN105747222A (en) | Composition having effects of lowering blood fat and reducing weight and application | |
CN102526477B (en) | Medicine composition for enhancing immunities as well as preparation method and application thereof | |
Zheng et al. | Endophytic Colletotrichum species from aquatic plants in southwest China | |
CN109453212A (en) | A kind of Fructus Terminaliae Billericae extract and its active component preparation method with antitumaous effect | |
Mechqoq et al. | Molecular docking, tyrosinase, collagenase, and elastase inhibition activities of argan by-products | |
Olaokun et al. | Molecular Docking and Molecular Dynamics Studies of Antidiabetic Phenolic Compound Isolated from Leaf Extract of Englerophytum magalismontanum (Sond.) TD Penn. | |
Murshed et al. | The Anticoccidial Effect of Alcoholic Vitis vinifera Leaf Extracts on Eimeria papillate Oocysts Isolated in Mice In Vitro and In Vivo | |
Bruno et al. | Chemical Composition, Biomolecular Analysis, and Nuclear Magnetic Resonance Spectroscopic Fingerprinting of Posidonia oceanica and Ascophyllum nodosum Extracts | |
Novotná et al. | Variability in nutrient use by orchid mycorrhizal fungi in two medium types | |
Zhu et al. | Modification of artichoke dietary fiber by superfine grinding and high-pressure homogenization and its protection against cadmium poisoning in rats | |
CN105687284A (en) | Extraction analysis and application method of mair-cona active constituents | |
CN102920847B (en) | Composition for strengthening immunity and preparation and application thereof | |
CN104142384A (en) | Method for screening active compounds capable of protecting or improving renal functions | |
CN107114790A (en) | A kind of health food of strengthen immunity and preparation method thereof | |
CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
Kanarek et al. | Application of Straw and Biopreparations as a Sustainable Method for Increasing the Organic Carbon Content and Chemical, Physical, and Biological Soil Properties in Spring Barley Culture | |
On-nom et al. | Nutritional Security: Carbohydrate Profile and Folk Remedies of Rare Edible Mushrooms to Diversify Food and Diet: Thailand Case Study | |
Piattino et al. | Lasiodiplodia iraniensis and Diaporthe spp. Are Associated with Twig Dieback and Fruit Stem-End Rot of Sweet Orange, Citrus sinensis, in Florida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20070530 |